The past two decades have witnessed an evolving understanding of the mitochondrial genome's (mtDNA) role in basic biology and disease. From the recognition that mutations in mtDNA can be responsible for human disease to recent efforts showing that mtDNA mutations accumulate over time and may be responsible for some phenotypes of aging, the field of mitochondrial genetics has greatly benefited from the creation of cell and animal models of mtDNA mutation. In this review, we critically discuss the past two decades of efforts and insights gained from cell and animal models of mtDNA mutation. We attempt to reconcile the varied and at times contradictory findings by highlighting the various methodologies employed and using human mtDNA disease as a guide to better understand cell and animal mtDNA models. We end with a discussion of scientific and therapeutic challenges and prospects for the future of mtDNA transfection and gene therapy.
residing in cytosolic mitochondria of one cell type becomes perpetually incorporated within the cytoplasm of the other cell type.
When generating cybrids, the extent of cytoplasmic material transfer has historically varied from purified mitochondria to potentially a donor cell's entire non-nuclear content. The nucleated cell accepting the cytoplasmic donation can also vary in terms of its make-up; the acceptor cell may or may not have undergone prior modification from its native state. In cybrid studies of mitochondrial function, the most commonly (but not exclusively) used approach involves transfer of mitochondria from enucleated or non-nucleated donor cells to cells previously depleted of their own endogenous mtDNA. This strategy creates cells in which the resultant cybrid contains nuclear DNA from one cell type and the mtDNA of another. An important tenet of this is that regardless of what cytoplasmic constituents are transferred, repeated divisions of the resultant cybrid cell dilutes to phenotypic irrelevancy any entity not capable of self-perpetuation. In healthy cells, the mtDNA is the best-recognized agent capable of replication and therefore perpetuation.
Cybrids created through mitochondrial transfer have been used for three distinct applications. The first application involves transfer of mitochondria containing a known mtDNA mutation ( Figure 1a ). This permits phenotypic assessment of the transferred mtDNA mutation.
Investigators can assess (among other things) whether the mutation alters electron transport chain activity, oxygen consumption rates, mitochondrial membrane potential, cell ATP levels, and cell growth rates. The second application involves transfer of mitochondria for which mtDNA has not already been characterized (Figure 1b ). This permits assessment of the integrity of the transferred mtDNA through biochemical and molecular assay of mitochondrial function or pathways affected by mitochondrial function. The third application relates to using cybrids for studies of bigenomic (mtDNA and nuclear DNA) compatibility.
The challenges faced with each type of application overlap to some degree, but some challenges uniquely relevant for one or the other applications exist. A better understanding of these challenges continues to emerge. Reviewing the history of cybrid research helps clarify the nature of these challenges, and provides perspective on the current and future state of cybrid research.
Cytoplasmic Fusion and ρ0 Cell Development: The First Wave
Combining enucleated cell material (cytoplasts) with nucleated cells (karyoplasts) goes back decades. One initial report from the early 1970's describes virus-mediated fusion (using inactivated Sendai virus) of enucleated mouse peritoneal macrophages and L929 murine cell cultures with the nucleated human HEp-2 cell line (96) . The term "cybrid" itself entered the literature in 1974, when Bunn et al. isolated cytoplasts from chloramphenicol-resistant mouse A9 cells and fused them with a nucleated chloramphenicol-sensitive mouse LMTK -cell line (12) .
The proposed term, a contraction of the phrase "cytoplasmic hybrid", represented modification of an existing term, "hybrid". The term hybrid refers specifically to the fusion product of two nucleated cells and therefore did not technically apply to the products of experiments such as these. Fusion in this early manuscript was also facilitated by exposure of cytoplasts and karyoplasts to inactivated Sendai virus. A related experiment followed in 1975, when Wallace et al. fused cytoplasts from a strain of chloramphenicol-resistant HeLa cells with a strain of chloramphenicol-sensitive HeLa cells (132) . The resultant cybrid line showed chloramphenicol resistance, demonstrating this biochemical feature was mtDNA and not nuclear DNA mediated.
Investigators working with this procedure over the next several years found polyethylene glycol (PEG) could also promote fusion of cytoplasts and karyoplasts to create cybrid cell lines (135) . It was further found that at least in some circumstances spontaneous cytoplast-karyoplast fusion could occur. In 1982, Clark and Shay reported a remarkably simple and straightforward experiment showing particular cell types incorporate exogenous mitochondria without direct investigator-mediated assistance (22) . In this case, the authors isolated mitochondria from a conditions. This guided explorations into the ability of cultured cell lines to similarly withstand mtDNA depletion.
Such intentionally mtDNA-depleted cells were referred to as "ρ depleted" cells. This nomenclature derived from the earliest report of cytoplasmic nucleic acid, from 1949, in which observed cytoplasmic nucleic acid was referred to as ρ nucleic acid (33 Dihydroorotate dehydrogenase, which is localized within mitochondria, catalyzes the conversion of dihydroorotic acid to orotic acid. Uridine is a pyrimidine pathway metabolite generated downstream of this synthetic step, and therefore bypasses the pyrimidine synthesis block that results from elimination of electron transport chain activity.
The following year, this group succeeded in producing an immortalized ρ0 LSCC-H32 avian fibroblast cell line (31) . Mitochondrial DNA from the parent cell line was taken from approximately 300 copies of mtDNA per untreated cell to undetectable levels. It is important to note that although these cells no longer contained detectable mitochondrial DNA (as assessed by Southern blotting), mitochondrial organelles nevertheless persisted. In fact, quantitative assessments showed proliferation of the residual mitochondrial organelles. Qualitatively, the residual mitochondrial organelles displayed swollen morphologies with disrupted cristae (78) .
The mitochondrial remnants from these avian ρ0 cells showed virtually no cytochrome oxidase activity, which was not surprising since three of the thirteen protein subunits are mtDNAencoded. Cell levels of cytochrome c, on the other hand, were increased. Subsequent investigators in the field have since labeled these mtDNA-depleted mitochondria "mitoids" (118) .
Soon after this, King and Attardi began efforts to deplete a human cell line of endogenous mtDNA (55) . These authors first reported creation of human osteosarcoma ρ0 lines, which they named 143B101 and 143B206 (56) . These lines were generated through chronic exposure of the parental cell line to ethidium bromide, which depleted the normal osteosarcoma mtDNA content from approximately 9,100 copies per cell to undetectable levels. In addition to showing uridine auxotrophy, both 143B osteosarcoma ρ0 lines were also auxotrophic for pyruvate (57) . The leading explanation for pyruvate auxotrophy relates to issues of anaerobic cell redox modulation.
An absence of oxidative phosphorylation deprives cells of a major NADH oxidation pathway. (50) . In cultured cell lines, rhodamine-6-G can also deplete mtDNA to levels low enough for effective production of cybrid cell lines that contain only exogenous, cytoplast-transferred mtDNA (137) .
Application of Cybrid Methodology for Basic Mitochondria and Human Disease Studies
During the early 1990's, the cybrid technique was applied to the study of mitochondrial encephalomyopathy diseases. The mitochondrial encephalomyopathies are a relatively rare group of disorders that were among the first diseases recognized to result from specific mutations of the mtDNA. Examples include the mitochondrial encephalopathy, lactic acidosis, and strokelike episodes (MELAS) syndrome, often caused by the A3243 mutation of the mtDNA tRNA Leu(UUR) gene, and the myoclonic epilepsy and ragged red fiber (MERRF) syndrome, often caused by the A8344G mutation of the mtDNA tRNA Lys gene. The causal mtDNA mutations are often heteroplasmic, meaning some but not all of the mtDNA copies within a cell possess the mutation.
The cybrid approach was used to assess the impact of these mutations on oxidative phosphorylation, and to address the "threshold" of mutational burden needed to cause an (23; 52) . Later cybrid studies of the G11778A mutation, performed using a nonosteosarcoma ρ0 cell line, also found a spectrophotometric reduction in complex I Vmax activity (11) .
Starting in the mid 1990's, investigators began using cybrids to assess the impact of mtDNA on electron transport chain enzyme function in persons with sporadic neurodegenerative diseases. The rationalization for this was that specific defects of the mitochondrial electron transfer chain were by this time recognized to occur in both Parkinson's disease (complex I) and
Alzheimer's disease (complex IV) (119) . In addition to occurring in the brains of affected patients, these enzymatic defects were also present in platelets. As mtDNA theoretically could either account for or contribute to the enzymatic lesions, and platelets are quite accessible, it seemed reasonable to transfer platelet mtDNA from persons with these diseases to ρ0 cells. The key conceptual distinction between this type of experiment and those already described is that in this case the nucleotide sequence of the transferred mtDNA was unknown. In this situation, biochemical assessments of cybrid cell lines would be used to screen the integrity and nature of the mtDNA used to restore the ρ0 cells to aerobic status.
A comprehensive discussion of sporadic neurodegenerative disease cybrid studies is beyond the scope of this manuscript; those interested in a more detailed discussion of some of these data may wish to consult other reviews dealing with this subject (38; 90; 107; 108; 113; 119) . To nevertheless summarize the available data, a large number of fairly large studies using either human neuroblastoma (SH-SY5Y) or human teratocarcinoma (NT2) ρ0 cell backgrounds found transfer of mtDNA from persons with Alzheimer's disease generated cybrid cell lines manifesting reduced complex IV activity, increased oxidative stress, altered calcium homeostasis, mitochondrial depolarization, increased beta amyloid production, increased cytoplasmic cytochrome c levels, caspase 3 activation, altered intracellular stress responses, decreased mitochondrial movement, and enhanced susceptibility to exogenous beta amyloid However, a single small study of Parkinson's disease cybrids that used a HeLa ρ0 cell background did not reveal any deficiency of oxidative phosphorylation (4).
In addition to this Alzheimer's disease and Parkinson's disease cybrid work, a cybrid study in which platelet mtDNA from persons with amyotrophic lateral sclerosis was used to repopulate SH-SY5Y ρ0 cells found evidence of electron transport chain dysfunction (especially in complex I), increased oxidative stress, and altered calcium homeostasis (116) . Another study using the osteosarcoma ρ0 cell background did not, though, find any alterations in electron transport chain function (37) . Studies of cybrids in which SH-SY5Y receive and express mtDNA from persons with progressive supranuclear palsy manifest reduced complex I activity and increased oxidative stress (1; 114).
A preponderance of published cybrid data therefore suggest mtDNA aberration occurs in at least some late-onset, sporadic neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and progressive supranuclear palsy). Many investigators, though, prefer not to accept this interpretation pending demonstration of actual specific mtDNA mutations. This undertaking has proven quite complicated for several reasons. First, the sporadic nature of these diseases makes it difficult to link causality to a particular sequence (108)).
Cybrid approaches have also proven useful in studies of mtDNA-nuclear DNA compatibility. The mitochondrial electron transport chain enzymes are large multimeric complexes that contain a mix of mtDNA and nuclear DNA-encoded subunits. As differences in electron transport chain-encoding genes have evolved over the course of evolution, selective pressure to keep all these bigenomically-produced proteins fitting and working together has existed within but not between species. Theoretically, with increasing mtDNA-nuclear DNA evolutionary divergence, increasingly feeble electron transport chain complexes should result.
Kenyon and Moraes applied a cybrid strategy to experimentally evaluate this prediction (53).
The authors transferred chimpanzee, gorilla, and orangutan mitochondrial to osteosarcoma ρ0 cells, thereby creating "xenomitochondrial cybrids". Xenomitochondrial cybrids produced via transfer of orangutan mitochondria to human osteosarcoma ρ0 cells were not viable. For the viable xenomitochondrial cybrids (containing chimpanzee and gorilla mtDNA), evolutionary divergence from humans was associated with reduced complex I activity (7).
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Cybrid Studies: Lessons Learned to Date
When it comes to cybrid work, no one standard approach exists. Technical variables figure prominently between laboratories. A partial list of these variables is provided in Table 1 .
It consistently appears whether a certain mtDNA species produces an altered electron transport or electron transport-related measure within a cybrid line depends a great deal on the background of the ρ0 line used to produce it. In general, it appears the more glycolytic the background of the utilized ρ0 line, the less likely its derivative cybrids will manifest oxidative deficits. It is therefore dangerous to assume simply removing mitochondria from glycolytic cells for use in biochemical assays somehow frees them of a glycolytic origin. On the contrary, it is already known mitochondria isolated from different tissues behave differently (64) . It is also possible mitigating nuclear factors render some cell lines less likely to manifest mitochondrial deficits (44) . For these reasons, some ρ0 lines may prove less effective than others for cybrid applications requiring detection of potentially subtle biochemical changes.
On a positive note, variation in the field will ultimately enhance our knowledge of mitochondrial biology and strengthen the veracity of cybrid experiment interpretations. On a negative note, in the short term these differences have perhaps generated confusion within the field and limited the impact of potentially important observations. At this time, it seems prudent to assume particular cybrid studies reaching different conclusions do not actually refute each other unless equivalent methods are utilized. Also, it is necessary to keep in mind that even though immortalized cell lines are aerobically active, such cells derive from neoplasms and in terms of energy metabolism are exceedingly glycolysis-dependent. Therefore, it is probably wise to use caution when extrapolating from studies of immortalized cybrid cell lines to differentiated or non-immortalized, heavily aerobic cell models. These methodological concerns also affect the concept of phenotypic threshold, where the level of a heteroplasmic mutation must be high in order to produce a measurable effect. If true, threshold may only be pertinent to the model in question and not be expandable to mitochondrial physiology in general.
Finally, as utilized to date for studies of mtDNA, one limitation of the cybrid technique is that mtDNA repopulation of ρ0 cells is accomplished as part of a greater cytoplast or mitochondrial transfer. Techniques allowing for repopulation of ρ0 cells with mtDNA isolates could substantially advance the state of the art of cybrid research.
Animal Models of MtDNA Biology
Animal models of mtDNA function and mutation are of great importance in elucidating mitochondrial biology. Due to the perceived technical difficulties of introducing mtDNA into cells, though, only a few such models exist.
The only known animal model possessing a homoplasmic mtDNA mutation was recently The lack of a simple method by which to transfer mtDNA alone in order to generate homoplasmic mtDNA animal models and the seemingly confounding animal mtDNA sequences have helped shift focus away from animal models of homoplasmic mutations. These technical difficulties have given rise to clever approaches to manipulate the mtDNA of animals. These manipulations include (1) introducing exogenous mitochondria and thus their mtDNA into ova and embryonic stem cells, (2) altering nuclear genes to affect rates of mtDNA mutation accumulation, (3) expression of a restriction enzyme targeted to mitochondria to induce mtDNA deletions, and (4) repeated backcrossing to study mtDNA within the context of differing nuclear genetic backgrounds. These approaches would be unnecessary if an mtDNA vector capable of transfecting mitochondria in the germ line or in vivo existed.
Cloned animals
Cloning of mammals is achieved by the fusion of an enucleated ovum with a somatic cell.
This procedure introduces a small amount of somatic cell mitochondria to the zygote and has been successfully applied to mice (47) and cattle (112) . The introduced mtDNA can be detected in various tissues in mice and remains stable during embryonic development. However, during adult life there is evidence of non-neutral segregation of introduced mtDNA, which achieves the highest concentrations in the liver, up to 14% (average 1.7%) (47).
The cybrid technique has been utilized on mouse embryonic stem (ES) cell lines in the hope of creating mtDNA transgenic mice (95) . This approach has proven successful despite significant technical hurdles and low efficiencies of viable births (74) .
Mitochondrial PstI mice
Intramitochondrial delivery of restriction enzymes has been used to effect changes in the heteroplasmic frequency of mtDNA variants in cell culture (111; 121) and in an animal model Elevated oxidative stress has been reported in patients with PEO (93) and is one of the hallmarks of normal human aging. It is known that many specific mtDNA mutations increase ROS production and therefore random mtDNA mutations were predicted to have the same effect by increasing the electron leak from the ETC. It is therefore difficult to interpret the absence of elevation in oxidative stress in the hypermutator mice as pertinent to either aging or classical mitochondrial disease. A possible way of reconciling these observations is that the accumulation of very high levels of both point mutations and deletions (much higher than in normal aging) results in the activation of signaling pathways that lead to a suppression of respiratory function by an ROS-independent mechanism. It is known that many forms of severe respiratory depression (e.g. due to mtDNA depletion in TFAM knockout mice (66) Cognitive capabilities, such as learning and memory, were found to be significantly influenced by mtDNA, while exploratory activity exhibited significant interactions between nuclear and mitochondrial influences. For example, the least intelligent strain, N, showed a quantitative, absolute improvement of 50% in the radial maze score (a test of learning) after receiving the H strain mtDNA, indicating a substantial cognitive boost provided by mtDNA.
Interestingly, the magnitude of the mtDNA impact on these measures increased with advancing age of the mice. As the mtDNA transferred between strains differed only in polymorphisms believed to be neutral, the apparent impact of such polymorphisms on cognitive functioning suggests they were not neutral after all.
Summary: Lessons from Animal Models of Mitochondrial Mutations
Available animal models of mtDNA mutation argue the importance of mtDNA to aging and disease. At the same time, they temper mechanistic interpretations of how mtDNA induces phenotypically relevant phenomena in these situations. Substantially improved knowledge of the full mtDNA mutational spectrum residing within tissues, coupled with better techniques of mtDNA transfer, will be necessary for further progress.
Mitochondrial Membranes and DNA Transfection
Though mitochondria were known to possess a separate genome, it was not until 1980 that the sequence of the human mitochondrial genome was published. Shortly thereafter, Clark and Shay were the first to successfully transfect the mitochondria of animal cells (22) . This first demonstration of successful transfection, however, would come to be ignored as the need for transfecting mitochondria seemed superlative at the time. In fact, it was commonly believed that mutations in mtDNA were incompatible with life since mtDNA encoded for proteins crucial to oxidative metabolism and thus unlikely to have meaningful biological sequelae. This was believed despite the fact that many decades earlier Otto Warburg and others had shown that many tumors lack any oxidative metabolism to speak of. Not until the first descriptions of mutations in mtDNA associated with human disease did the need for mtDNA transfection become apparent. By then the efforts of Clark and Shay were all but forgotten. To enable the study of mtDNA mutations associated with human disease, cybrid technology was developed as it became generally accepted mitochondria of animal cells were not amenable to transfection.
Mitochondria traditionally have been described as organelles possessing a double membrane with little permeability but the capacity to import macromolecules through defined pores. Generally, these import activities are energy dependent and the macromolecules limited to proteins, metabolites and lipids. The view of mitochondria as organelles impenetrable to nucleic acids has been so generally accepted as to frustrate efforts to deliver nucleic acids to the mitochondrial matrix. Since the only entry point to the mitochondrial matrix is through macromolecular pores, delivering full-length mitochondrial genomes is akin to a camel passing through the eye of a needle.
Informed by this view, investigators designed clever attempts to utilize the mitochondrial protein import machinery for manipulating mitochondrial genes. These efforts have been broadly In the direct approach, MLS (Mitochondrial Leader Sequence), peptide motifs involved in mitochondrial import of many cytoplasmically translated proteins are utilized. These MLScontaining peptides are conjugated to nucleic acids (134) . This includes PNAs (Peptide Nucleic Acids) (19) and oligonucleotides (34; 60). However, no long DNA molecules, much less fulllength mtDNA, have yet been delivered to mitochondria in mammalian cells using these methods.
In the indirect approach, also termed allotopic expression, mtDNA recoded for cytoplasmic translation is targeted to the nucleus and directs the production of proteins that are then imported to the mitochondria using TOM/TIM import machinery. Possibly due to their high hydrophobicity, to date only four mitochondrial genes have been corrected in this manner, in plants (94) , yeast (99) and in cell culture (43) , (85), (140) . This approach is limited by the general difficulties of nuclear gene therapy, as well as problems with aggregation of some of the allotopic proteins (85) . Additionally, many pathological mitochondrial mutations are in mitochondrial RNA (transfer and ribosomal) genes and therefore cannot be corrected with allotopic expression alone. This approach is further confounded by the complex issue of controlling expression of allotopic mitochondrial genes. Finally, since the mutated gene is not removed from mitochondria, its product may still cause damage through toxic gain-of-function mechanisms, such as generation of ROS after incorporation into the electron transport chain.
In a hopeful turn, the indirect approach has been used to target proteins not normally present in mitochondria, such as restriction enzymes. In a small subset of mitochondrial disease patients, the causative mutation produces a new restriction site in the mitochondrial genome.
Genomes with such abnormal restriction sites are specifically degraded by the appropriate restriction enzyme while wild-type mtDNA present in the same cell is left intact. In two cell culture studies this strategy allowed shifting of heteroplasmic ratios towards the wild-type (111), (121) . However, this approach is in principle limited to patients with abnormal restriction sites but has shown promise in vivo (8) .
Methods in Mitochondrial Transfection
Delivery of mtDNA to the mitochondria of yeast was achieved using a biolistic (biological ballistic) gun (3) but it has thus far not been reported in mammalian cells. Full-length mtDNA has been delivered to mammalian ova by injection of cytoplasm and used in an assistive reproductive technology in humans (67); however, this method cannot be adapted for therapeutic use in patients with pre-existing disease. Nevertheless, experiments using similar approaches (cytoplasmic fusion) have shown that the proportion of mutated to normal mtDNA influences the phenotype. Fewer abnormalities are seen as the proportion of abnormal mtDNA is decreased.
Cells with less mutant mtDNA have more resistance to UV light and certain poisons, lower risk of becoming cancerous, lower ROS output, and better respiratory function (70), (14), (92), (18) .
This indicates that the addition of normal mtDNA could shift abnormal cells towards a healthier phenotype, as evidenced by the indirect restriction enzyme strategy described above (8) . Shrinkage of the mitochondrial genome requires mechanism(s) for gene transfer to the nucleus. How this occurs remains unclear, but increasing evidence supports the possibility of direct nucleic acid passage across the mitochondrial membrane through porin channels (62) .
Investigators, recognizing that mitochondria have a bacterial origin, have utilized both electroporation and bacterial conjugation to successfully deliver mtDNA, presumably through porin channels as happens in bacteria (24) (138) . Mitochondria can also acquire genetic material, potentially through a similar mechanism. For instance, HIV-1 RNA can accumulate rapidly in mitochondria of infected lymphocytes, within hours of stimulation of viral expression (109) . The mitochondria of plants and protozoa contain nuclear-encoded tRNA's (39), and mammalian mitochondria contain the nuclear-encoded RNA subunit of a mitochondrial RNA-processing endonuclease (97) . Beef heart mitochondrial porin incorporated into a planar bilayer membrane was shown to allow passage of double-stranded DNA across an electrical field gradient (120) and plant mitochondria import DNA through porin in a way that involves mitochondrial permeability transition (61) . This provides both a mechanism for DNA entry into mitochondria and a potential vulnerability of mitochondria to transfection by foreign DNA.
The striking similarities between mitochondria and bacteria enable a curious possibility, that mitochondria may yet be amenable to bacteriophage virus mediated transfection. In fact, proteins is membrane potential and translocase independent. Given import of plasmid DNA into mitochondria in a recent study was also independent of membrane potential and the translocase machinery suggests a novel mechanism through which mitochondria import macromolecules exists (62) . In fact, these recent studies suggest mitochondrial membranes are not impenetrable barriers, and that the mitochondrial and plasma membranes exchange components.
Mitochondrial membranes, therefore, appear more dynamic than previously thought.
Summary: MtDNA Gene Therapy
For the successful transport of DNA to mitochondria in living cells, the delivery system must (1) bind the DNA; (2) neutralize the negative charge of the DNA; (3) protect the DNA from proteolytic degradation; (4) mediate the cellular uptake of DNA across lipid membranes; (5) transport the DNA to mitochondria; (6) cross the double mitochondrial membrane; and (7) present the DNA to the mitochondrial matrix in a form suitable for replication and transcription.
Binding of DNA to protect against degradation and mediate intracellular uptake has to date been accomplished by a variety of substances, from lipids and polymers to viruses and recombinant proteins such as histones. Some of these approaches are currently in clinical trials for nuclear gene therapy. The challenge of how to transport DNA through the cytosol and specifically into mitochondria of living animals, though, has not been satisfactorily addressed. This hurdle must be overcome if clinically effective mitochondrial gene therapy approaches are to be realized. 
